GlassScriptPhysician profile
Marquand Patton
NPI 1457617516
$111,890.36
in general payments reported to CMS, 2019-2025
45 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,627 · 2020: $5,374 · 2021: $11K · 2022: $34K · 2023: $16K · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,484.75 |
| Food and Beverage | $14,423.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,587.50 |
| Travel and Lodging | $3,943.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $35,930.53 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Angiodynamics, INC. | $31,942.41 | 2021-2025 | Angiovac, Alphavac, Nanoknife |
| Abbott Laboratories | $16,754.25 | 2019-2025 | Aveir, Navitor, Epic |
| Shockwave Medical, INC | $5,251.56 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Livanova USA, INC. | $4,850.51 | 2023-2024 | Lifesparc |
| Medtronic, INC. | $4,378.46 | 2021-2025 | Onyx Frontier, Turbohawk, Mosaic |
| Abiomed | $2,843.75 | 2022-2023 | Impella |
| Edwards Lifesciences Corporation | $2,271.64 | 2019-2025 | Sapien 3 Ultra Resilia |
| Atricure, INC. | $1,792.02 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $731.95 | 2019-2025 | |
| Amgen INC. | $485.05 | 2019-2021 | |
| Pfizer INC. | $465.99 | 2021-2025 | |
| Medtronic Vascular, INC. | $326.72 | 2019-2020 | |
| Endologix LLC | $319.03 | 2025 | Torus Stent Graft System, Endocross Device |
| Argon Medical Devices, INC. | $288.38 | 2024-2025 | Clot Management, Clot Management |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marquand Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.